Philidor unfairly tarnishes specialty pharmacies | Private sector seeks to address drug pricing | Many consumers won't be able to avoid paying more for health coverage
November 19, 2015
PCMA SmartBrief
News for the PBM Industry

Featured Story
Philidor unfairly tarnishes specialty pharmacies
Philidor Rx Services has been inaccurately characterized as a specialty pharmacy in coverage of its relationship with drugmaker Valeant Pharmaceuticals International. Inappropriate ties to drugmakers are not typical of specialty pharmacies, said F. Randy Vogenberg of Access Market Intelligence. AIS Health/Specialty Pharmacy News (11/19)
Share: LinkedInTwitterFacebookGoogle+Email
Legislative & Regulatory News
Private sector seeks to address drug pricing
Payers and pharmaceutical companies are exploring ways to base pricing on effectiveness as well as indication-based payments. Politico Pro (subscription required) (11/18)
Share: LinkedInTwitterFacebookGoogle+Email
Many consumers won't be able to avoid paying more for health coverage
An analysis of health plans available in a selection of counties finds that many consumers will not be able to avoid paying more for health insurance by shopping for a different plan than their current coverage. The Wall Street Journal (tiered subscription model) (11/18)
Share: LinkedInTwitterFacebookGoogle+Email
House committee plans hearing on drugmakers' pricing practices
The House Committee on Oversight and Government Reform has scheduled a hearing in early 2016 to examine the drug-pricing practices of Turing Pharmaceuticals, Valeant Pharmaceuticals and other drugmakers. Committee member Rep. Elijah Cummings, D-Md., urged Rep. Jason Chaffetz, R-Utah, the committee chairman, to issue subpoenas to force the drugmakers to cooperate with the investigation. Chaffetz's spokeswoman, M.J. Henshaw, said subpoenas will not be issued now because the committee's investigation is still in its early stages. The Hill (11/18)
Share: LinkedInTwitterFacebookGoogle+Email
Possible Pfizer-Allergan merger raises corporate tax issue
Negotiations for the acquisition of Dublin-based Allergan by Pfizer for an estimated $150 billion have raised concerns that Pfizer could move its headquarters abroad to lower taxes, a process known as corporate inversion. The US Treasury said it could not stop such inversions without new congressional legislation. The New York Times (free-article access for SmartBrief readers) (11/18)
Share: LinkedInTwitterFacebookGoogle+Email
State Medicaid programs denying hepatitis C treatments at high rates
A number of states are denying hepatitis C treatments to almost 50% of Medicaid applicants, compared with denial rates of about 5% for Medicare and 10% for private insurance programs, according to a study presented at the Liver Meeting 2015. "Incomplete data to determine medical need" and "lack of medical necessity" were the most commonly cited reasons for denials. Medscape (free registration) (11/18)
Share: LinkedInTwitterFacebookGoogle+Email
Drug Industry Spotlight
Nasal formulation of naloxone approved as overdose treatment
The FDA has approved a nasal spray version of Adapt Pharma's Narcan, or naloxone, for the reversal of opioid overdose. Adapt CEO Seamus Mulligan said the drug would be priced at $37.50 per unit for Medicaid, emergency services and certain other buyers; he did not specify a list cost but said pricing would be "responsible." STAT (11/18)
Share: LinkedInTwitterFacebookGoogle+Email
Hard work spotlights the character of people: Some turn up their sleeves, some turn up their noses, and some don't turn up at all."
-- Sam Ewing,
baseball player
Share: LinkedInTwitterFacebookGoogle+Email
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 253 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information